Effects of gastric inhibitory polypeptide, vasoactive intestinal polypeptide and peptide histidine isoleucine on the secretion of hormones by isolated mouse pancreatic islets.

Bailey CJ, Wilkes LC, Conlon JM, Armstrong PH, Buchanan KD

The Journal of endocrinology1 Jun 1990Cited by 8 (Europe PMC)

PMID1973701DOI10.1677/joe.0.1250375PepBankPUB-01973701

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

01LabEx vivo tissueEfficacy outcome
In isolated mouse islets, VIP at 1 mumol/l enhanced insulin release at 5.6 mmol glucose/l.
In plain wordsIn lab tests on mouse pancreatic islets, VIP increased insulin release when glucose was at a lower level.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseInsulin release at 5.6 mmol glucose/l
Study
mousen: not reported in source
isolated pancreatic islets
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
1 mumol/l · 30 minAs given in this study (mouse).
Source sentences
Summary
Insulin release was enhanced (greater than 50%) by GIP (100-1000 nmol/l) and VIP (1 mumol/l) at 5.6 mmol glucose/l
1 context sentence(design, population, supporting numbers)
Summary · context
The release of insulin, glucagon, somatostatin and pancreatic polypeptide (PP) by isolated mouse pancreatic islets was determined during 30-min incubations at 5.6 and 16.7 mmol glucose/l in the absence and presence of gastric inhibitory polypeptide (GIP), vasoactive intestinal polypeptide (VIP) and…
Report a problemFND-0197370101
02LabEx vivo tissueEfficacy outcome
In isolated mouse islets, VIP at 1 mumol/l did not enhance insulin release at 16.7 mmol glucose/l.
In plain wordsIn lab tests on mouse pancreatic islets, VIP did not increase insulin release when glucose was at a higher level.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeInsulin release at 16.7 mmol glucose/l
Study
mousen: not reported in source
isolated pancreatic islets
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
1 mumol/l · 30 minAs given in this study (mouse).
Source sentences
Summary
Insulin release was enhanced (greater than 50%) by GIP (100-1000 nmol/l) and VIP (1 mumol/l) at 5.6 mmol glucose/l, but not at 16.7 mmol glucose/l.
1 context sentence(design, population, supporting numbers)
Summary · context
The release of insulin, glucagon, somatostatin and pancreatic polypeptide (PP) by isolated mouse pancreatic islets was determined during 30-min incubations at 5.6 and 16.7 mmol glucose/l in the absence and presence of gastric inhibitory polypeptide (GIP), vasoactive intestinal polypeptide (VIP) and…
Report a problemFND-0197370102
03LabEx vivo tissueEfficacy outcome
In isolated mouse islets, VIP at 1-1000 nmol/l increased glucagon release at both glucose concentrations in a dose-related manner.
In plain wordsIn lab tests on mouse pancreatic islets, VIP increased glucagon release, and more VIP gave more release.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseGlucagon release
Study
mousen: not reported in source
isolated pancreatic islets
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
1-1000 nmol/l · 30 minAs given in this study (mouse).
Source sentences
Summary
Glucagon release was increased by GIP (100-1000 nmol/l), and by VIP and PHI (1-1000 nmol/l) at both glucose concentrations in a dose-related manner (maximum increases greater than tenfold).
1 context sentence(design, population, supporting numbers)
Summary · context
The release of insulin, glucagon, somatostatin and pancreatic polypeptide (PP) by isolated mouse pancreatic islets was determined during 30-min incubations at 5.6 and 16.7 mmol glucose/l in the absence and presence of gastric inhibitory polypeptide (GIP), vasoactive intestinal polypeptide (VIP) and…
Report a problemFND-0197370103
04LabEx vivo tissueEfficacy outcome
In isolated mouse islets, VIP at 1-1000 nmol/l reduced somatostatin release by more than 37% at 16.7 mmol glucose/l.
In plain wordsIn lab tests on mouse pancreatic islets, VIP reduced somatostatin release when glucose was at a higher level.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseSomatostatin release at 16.7 mmol glucose/l
Study
mousen: not reported in source
isolated pancreatic islets
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
1-1000 nmol/l · 30 minAs given in this study (mouse).
Source sentences
Summary
whereas PHI and VIP (1-1000 nmol/l) reduced (greater than 37%) somatostatin release at 16.7 mmol glucose/l.
1 context sentence(design, population, supporting numbers)
Summary · context
The release of insulin, glucagon, somatostatin and pancreatic polypeptide (PP) by isolated mouse pancreatic islets was determined during 30-min incubations at 5.6 and 16.7 mmol glucose/l in the absence and presence of gastric inhibitory polypeptide (GIP), vasoactive intestinal polypeptide (VIP) and…
Report a problemFND-0197370104
05LabEx vivo tissueEfficacy outcome
In isolated mouse islets, VIP did not significantly alter pancreatic polypeptide release.
In plain wordsIn lab tests on mouse pancreatic islets, VIP did not clearly change release of pancreatic polypeptide.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changePancreatic polypeptide release
Study
mousen: not reported in source
isolated pancreatic islets
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
Dose not stated · 30 minAs given in this study (mouse).
Source sentences
Summary
but was not significantly altered by VIP, and was reduced (39-56%) by PHI.
1 context sentence(design, population, supporting numbers)
Summary · context
The release of insulin, glucagon, somatostatin and pancreatic polypeptide (PP) by isolated mouse pancreatic islets was determined during 30-min incubations at 5.6 and 16.7 mmol glucose/l in the absence and presence of gastric inhibitory polypeptide (GIP), vasoactive intestinal polypeptide (VIP) and…
Report a problemFND-0197370105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.